Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Neuropharmacology ; 45(5): 594-604, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12941373

RESUMEN

The analgesic potential of cannabinoids may be hampered by their ability to produce aversive emotion when administered systemically. We investigated the hypothesis that the midbrain periaqueductal grey (PAG) is a common substrate mediating the anti-nociceptive and potential aversive effects of cannabinoids. The rat formalin test was used to model nociceptive behaviour. Intra-PAG microinjection of the excitatory amino acid D,L-homocysteic acid (DLH) was used to induce an aversive, panic-like reaction characteristic of the defensive "fight or flight" response. Administration of the cannabinoid receptor agonist HU210 (5 microg/rat) into the dorsal PAG significantly reduced the second phase of formalin-evoked nociceptive behaviour, an effect which was blocked by co-administration of the CB(1) receptor antagonist SR141716A (50 microg/rat). This anti-nociceptive effect was accompanied by an HU210-induced attenuation of the formalin-evoked increase in Fos protein expression in the caudal lateral PAG. Intra-dorsal PAG administration of HU210 (0.1, 1 or 5 microg/rat) significantly reduced the aversive DLH-induced explosive locomotor response. The anti-nociceptive effect of HU210 is likely to result from activation of the descending inhibitory pain pathway. Mechanisms mediating the anti-aversive effects of cannabinoids in the PAG remain to be elucidated. These data implicate a role for the PAG in both cannabinoid-mediated anti-nociceptive and anti-aversive responses.


Asunto(s)
Agonistas de Receptores de Cannabinoides , Dronabinol/análogos & derivados , Dronabinol/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Homocisteína/análogos & derivados , Dolor/tratamiento farmacológico , Sustancia Gris Periacueductal/efectos de los fármacos , Análisis de Varianza , Animales , Conducta Animal , Desinfectantes , Relación Dosis-Respuesta a Droga , Dronabinol/uso terapéutico , Combinación de Medicamentos , Reacción de Fuga/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Formaldehído , Homocisteína/toxicidad , Inmunohistoquímica/métodos , Masculino , Microinyecciones , Movimiento/efectos de los fármacos , Dolor/inducido químicamente , Dimensión del Dolor/efectos de los fármacos , Sustancia Gris Periacueductal/anatomía & histología , Piperidinas/administración & dosificación , Proteínas Proto-Oncogénicas c-fos/metabolismo , Pirazoles/administración & dosificación , Ratas , Ratas Sprague-Dawley , Rimonabant , Factores de Tiempo
2.
Plant Physiol ; 52(1): 79-81, 1973 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16658505

RESUMEN

Various chemicals were applied to dry seeds by means of organic solvents. The gibberellic acid-treated (1 mm) lettuce seeds (Lactuca sativa L.) germinated nearly 100% in the dark even after prolonged storage, and those treated with abscisic acid (1 mm or 0.5 mm) failed to germinate in the light. The seedlings emerging from morphactin-treated (1 mm) cucumber seeds (Cucumis sativus L.) exhibited profound changes in morphology. Different combinations of hormones applied to lettuce seeds caused a promotion or an inhibition of germination. Germination promotion or inhibition studies showed that the applied chemicals could be removed by washing with an organic solvent or water. Progressively larger amounts of chemicals were removed with increasing periods of washing. Thus the chemical appeared to penetrate the seed to some degree. The potential of the organic solvent method is discussed.

3.
Eur J Neurosci ; 19(3): 678-86, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14984418

RESUMEN

The antinociceptive effects of Delta9-tetrahydrocannabinol (Delta9-THC) have been widely described; however, its therapeutic potential may be limited by secondary effects. We investigated whether coadministration of low doses of cannabinoids or cannabinoids and morphine produced antinociception in the absence of side-effects. Effects of preadministration (i.p.) of Delta9-THC (1 or 2.5 mg/kg), cannabidiol (5 mg/kg), morphine (2 mg/kg), Delta9-THC + morphine, Delta9-THC + cannabidiol or vehicle on formalin-evoked nociceptive behaviour were studied over 60 min. Trunk blood and brains were collected 60 min after formalin injection and assayed for corticosterone and tissue levels of monoamines and metabolites, respectively. Drug effects on locomotor activity, core body temperature and grooming were assessed. Delta9-THC reduced both phases of formalin-evoked nociceptive behaviour, enhanced the formalin-evoked corticosterone response and increased the 4-hydroxy-3-methoxyphenylglycol : noradrenaline ratio in the hypothalamus. Cannabidiol alone had no effect on these indices and did not modulate the effects of Delta9-THC. Morphine reduced both phases of formalin-evoked nociceptive behaviour. Coadministration of Delta9-THC and morphine reduced the second phase of formalin-evoked nociceptive behaviour to a greater extent than either drug alone, and increased levels of thalamic 5-hydroxytryptamine. While the antinociceptive effects of Delta9-THC and morphine alone occurred at doses devoid of effects on locomotor activity, coadministration of Delta9-THC and morphine inhibited locomotor activity. In conclusion, coadministration of a low dose of morphine, but not cannabidiol, with Delta9-THC, increased antinociception and 5-hydroxytryptamine levels in the thalamus in a model of persistent nociception. Nevertheless, these enhanced antinociceptive effects were associated with increased secondary effects on locomotor activity.


Asunto(s)
Monoaminas Biogénicas/metabolismo , Dronabinol/uso terapéutico , Morfina/uso terapéutico , Narcóticos/uso terapéutico , Dolor/tratamiento farmacológico , Animales , Conducta Animal/efectos de los fármacos , Temperatura Corporal/efectos de los fármacos , Encéfalo/anatomía & histología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Química Encefálica , Cannabidiol/uso terapéutico , Cromatografía Líquida de Alta Presión , Corticosterona/sangre , Modelos Animales de Enfermedad , Interacciones Farmacológicas , Formaldehído , Masculino , Actividad Motora/efectos de los fármacos , Dolor/inducido químicamente , Dolor/fisiopatología , Dimensión del Dolor , Psicotrópicos/uso terapéutico , Radioinmunoensayo , Ratas , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA